- Amid prosperous product launches and new drug approvals, Johnson & Johnson and Genentech have something else to brag about: being two of Glassdoor's annual "50 Best Places to Work."
- The companies ranked 26 and 32, and were the only biopharma representation on the online job reviewer's annual employee choice list. Filling the top slots for the 2017 installment were consulting firm Bain & Company, a step up from its second place finish last year, Facebook, Boston Consulting Group, Google and World Wide Technology.
- Johnson & Johnson returns to the list, which started in 2009, following a five-year hiatus. Genentech, meanwhile, dropped 15 spots from its 2016 placement.
The list is part of Glassdoor's Employee's Choice Awards, which also include a category for best rated CEOs that comes out in June, as well as collections of the best jobs and cities for employment.
Glassdoor chooses winners based on anonymous reviews that employees from a wide range of companies submit. The reviews ask for basic information and opinions about the company, such as the pros and cons of working there, advice to management on how the organization can improve, and a one- to five-star satisfaction rating.
From those pile of reviews, Glassdoor uses its own algorithm that "considers the quality, quantity, and consistency of reviews," to determine the overall rankings.
Johnson & Johnson received an average 4.3 stars from reviews while Genentech had 4.2. Notably, the difference between first place Bain & Co., which scored 4.6, and 50th place Wegmans Food Markets was only four-tenths of a star.
Johnson & Johnson also made Glassdoor's Highest Rated CEOs compilation for the last three years, seeing its best finish in 2016 when it placed 16th.
Genentech made that list for its first time this year, coming in at 22nd. The Roche subsidiary has appeared on the Best Places to Work list five times, however, reaching 17th place both in 2015 and in 2009.
Additionally, Roche and Bristol-Myers Squibb, who were in last year's installment of Best Places to Work, fell off completely, as did Bayer's recent acquisition Monsanto.